SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
STC Biologics, Inc Receives $2.5 Million SBIR Phase II Contract From the National Cancer Institute to Continue Biosimilar Development for the Treatment of Cancer